论文部分内容阅读
cbl-b(casitas B cell lymphoma-b)是cbl家族中的一员,与cbl有79%的同源性,由于最早是从人乳腺癌中分离获得,故名cbl-b。沉默cbl-b后CD8~+T细胞可避开其激活时对共刺激信号CD28的依赖,细胞大量增殖并分泌大量的IL-2,同时也可以使T细胞对于TGF-β的抑制作用的敏感性降低。这一特性使其在肿瘤治疗上有广泛的应用前景,成为近年来的研究热点。本文介绍了cbl-b的结构与功能、cbl-b的表达调控及在肿瘤免疫治疗中的研究与应用,以期在肿瘤治疗中提供一定参考。
cbl-b (casitas B cell lymphoma-b) is a member of cbl family, with cbl 79% homology, since the earliest is isolated from human breast cancer, hence the name cbl-b. After silencing cbl-b, CD8 + T cells can avoid the activation of CD8 dependent costimulatory cells, proliferate large numbers of cells and secrete large amounts of IL-2, but also can make T cells sensitive to the inhibitory effect of TGF-β Sexual reduction. This feature makes it a wide range of applications in the treatment of cancer has become a research hot spot in recent years. This article describes the structure and function of cbl-b, cbl-b expression and regulation of tumor immunotherapy research and application, with a view to provide some reference in the treatment of cancer.